Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides. METHODS: We sequenced the exons of ANGPTL4 in samples obtain from 42,930 participants of predominantly European ancestry in the DiscovEHR human genetics study. We performed tests of association between lipid levels and the missense E40K variant (which has been associated with reduced plasma triglyceride levels) and other inactivating mutations. We then tested for associations between coronary artery disease and the E40K variant and other inactivating mutations in 10,552 participants with coronary artery disease and 29,223 controls. We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid levels in mice and monkeys. RESULTS: We identified 1661 heterozygotes and 17 homozygotes for the E40K variant and 75 participants who had 13 other monoallelic inactivating mutations in ANGPTL4. The levels of triglycerides were 13% lower and the levels of high-density lipoprotein (HDL) cholesterol were 7% higher among carriers of the E40K variant than among noncarriers. Carriers of the E40K variant were also significantly less likely than noncarriers to have coronary artery disease (odds ratio, 0.81; 95% confidence interval, 0.70 to 0.92; P=0.002). K40 homozygotes had markedly lower levels of triglycerides and higher levels of HDL cholesterol than did heterozygotes. Carriers of other inactivating mutations also had lower triglyceride levels and higher HDL cholesterol levels and were less likely to have coronary artery disease than were noncarriers. Monoclonal antibody inhibition of Angptl4 in mice and monkeys reduced triglyceride levels. CONCLUSIONS: Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers. The inhibition of Angptl4 in mice and monkeys also resulted in corresponding reductions in these values. (Funded by Regeneron Pharmaceuticals.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, inactivating variants in ANGPTL4, a key inhibitor of LPL, have been shown to reduce levels of TGs, LDL-C, and HDL-C. Individuals with these variants exhibit lifelong reductions in circulating TGs and up to a 19% lower risk of CAD [26].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like mice, humans deficient in ANGPTL3, ANGPTL4, or ANGPTL8 have lower plasma triglycerides (56–58, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
GCTA: a tool for genome-wide complex trait analysis
Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.11.011 · Cited by 8,279
Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
A solution to the problem of separation in logistic regression
Heinze, G., & Schemper, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1047 · Cited by 2,711
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Li, B., & Leal, S. M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.024 · Cited by 1,527
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Research works printed but not linked: 2
- Van der Auwera GA, 2013, Curr Protoc Bioinformatics, 11, 11.10.1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Items 401–497 of 497
Liu, Q., Wang, P., Zhao, Y., Dai, Y., Ye, Z., & Wang, S. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904131 · Cited by 2
Genome-First Approach to Rare and Common Variant Risk of Thoracic Aortic Aneurysm and Dissection
DePaolo, J. S., Smelser, D. T., Guo, D., Abramowitz, S. A., Biagetti, G. M., Judy, R., Desai, N. D., Szeto, W. Y., Levin, M. G., Mirshahi, H. S., et al. (2024) · JVS Vascular Science · doi:10.1016/j.jvssci.2024.100243 · Cited by 2
Self-citationRNA inosine sensor-guided TadA mutational scanning for toxicity minimization of adenine base editors
Zhang, C., Chen, Z., Cao, J., Zhang, Z., Li, W.-K., Zhang, X., Chen, J., Liu, J., Yuan, Z., Gao, F., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.011 · Cited by 3
Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent
Marston, N., & Zimerman, A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001013 · Cited by 3
Nordestgaard, A. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01393-4 · Cited by 3
Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5
Yang, Y., Smith, S. A., Chen, Y. Q., Li, H., Zhen, E. Y., Sloan, J. H., Siegel, R. W., Qian, Y., Wen, Y., Jung, H., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101050 · Cited by 2
Bitencourt, I. C., Zimerman, A., & Marston, N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01441-z · Cited by 2
“…the management of dyslipidemia to reduce cardiovascular risk has centered on strategies that enhance particle clearance via the low-density lipoprotein receptor (LDLR), such as statins, ezetimibe, and supporting a potential causal role of the ANGPTL pathway in cardiometabolic disease risk [5–7].”
Effects of evolving lipid-lowering drugs on carbohydrate metabolism
Tsimihodimos, V., & Elisaf, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.012 · Cited by 2
Kaltoft, M., Langsted, A., & Nordestgaard, B. G. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2022.2.e20 · Cited by 2
Medicinal Herbs as an Alternative Treatment in the Management of Hyperlipidemia
Sen, A. K., Balaraman, R., Sen, D. B., Dash, D. K., & Maheshwari, R. A. (2023) · Journal of Natural Remedies · doi:10.18311/jnr/2023/32174 · Cited by 2
Liu, Y., Lin, H., Liu, M., Lin, L., & Wen, Y. (2024) · Psychiatry Investigation · doi:10.30773/pi.2024.0011 · Cited by 2
Incorporating Pharmacogenomics in Drug Development
Yin, O. Q. P., & Vandell, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00003-6 · Cited by 3
ASGR1 - a new target for lowering non-HDL cholesterol
Hassan, M. S., & Wagdy, K. (2016) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.14 · Cited by 4
Therapeutic antagonism of ANGPTL4
Luo, F., Chen, C., Chen, S., Wu, P., & Fang, Z. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.054 · Cited by 2
Sin‐Chan, P., Gosalia, N., Gao, C., Hout, C. V. V., Ye, B., Marcketta, A., Li, A. H., O’Dushlaine, C. T., Li, D., Overton, J. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.19.188789 · Cited by 2
“GHS serves a largely unselected population of >1.6 million participants from central Pennsylvania who are of predominantly European ancestry (Abul-Husn et al., 2016; Dewey et al., 2017; Dewey et al., 2016).”
BackgroundInfluentialSelf-citationSylvers-Davie, K. L., & Davies, B. S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00125-0 · Cited by 2
Lipoprotein profile and metabolic fine-mapping of genetic lipid risk lociPreprint
Suhre, K., AL-Ishaq, R. K., Belkadi, A., Habib, T., Halama, A., Stephan, N., Thareja, G., Zaghlool, S. B., Fauman, E. B., & Najafi-Shoushtari, S. H. (2022) · medRxiv · doi:10.1101/2022.06.12.22276286 · Cited by 3
Metabolic reprogramming by endothelial ANGPTL4 depletion protects against diabetic kidney diseasePreprint
Srivastava, S. P., Zhou, H., Shenoi, R., Morris, M., Lainez, B., Takagaki, Y., Rajendran, B. K., Setia, O., Aryal, B. K., Kanasaki, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.08.652142 · Cited by 2
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Ohara, M., Terasaki, M., Ito, Y., Yamagishi, S.-I., & Mori, Y. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65941 · Cited by 2
“ANGPTL4 loss-of-function mutations are associated with decreased TGs and increased HDL-C levels, suggesting a causal role of elevated ANGPTL4 in dyslipidemia 39) .”
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Kidney angiopoietin-like protein 4 regulates fibrotic responses in diabetic kidney disease
Srivastava, S. P., Arora, A., Hamed, M., Urval, A., Dupati, A., Xia, S., Yoshida, S., & Inoki, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1803412 · Cited by 1
“In one study, Dewey et al. used a neutralizing antibody of ANGPTL4 in both humanized mice and nonhuman primates, which resulted in severe side effects and systemic metabolic abnormalities (Dewey et al., 2016).”
Aghasizadeh, M., Ahmadihoseini, A., Sahebi, R., Kazemi, T., Asadiyan‐Sohan, P., Esmaily, H., Samadi, S., Avan, A., Ferns, G. A., Bizhaem, S. K., et al. (2024) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2418 · Cited by 1
“…ANGPTL3- 4-8 model, reviews confirmed that LOF variants in ANGPTL4 reduced cardiovascular risk and Other researchers corroborated these findings (Dewey et al., 2016; Folsom et al., 2008; Peloso et al., 2014; Quagliarini et al., 2012; Romeo et al., 2007, 2009; Smart-Halajko et al., 2011)…”
ResultAlenazi, M. M., Sabico, S., Alnaami, A. M., Wani, K., Hussain, S. D., & Al‐Daghri, N. M. (2024) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2024.103469 · Cited by 1
Bubnova, M. G., Ezhov, M. V., Aronov, D. M., Galyаvich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Cardiosomatics · doi:10.17816/cs688224 · Cited by 1
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study
Chen, Z., Triatin, R. D., Luo, L., Snieder, H., Schmidt, A. F., Ditmarsch, M., Kastelein, J. J. P., Dullaart, R. P. F., Kuivenhoven, J. A., & Thio, C. H. L. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03209-w · Cited by 1
“ANGPTL3 for example does not only inhibit LPL but also endothelial lipase [83–85] which together results in reductions of HDL-C, LDL-C, and TG. ANG-PTL4 primarily acts through inhibiting LPL which results in a decrease in TG and an increase in HDL-C [86–88].”
Die Rolle seltener Varianten bei häufigen Krankheiten
Ludwig, K. U., Degenhardt, F., & Nöthen, M. M. (2019) · Medizinische Genetik · doi:10.1007/s11825-019-0246-2 · Cited by 1
Tsunoda, T. (2019) · Springer eBooks · doi:10.1007/978-981-13-8177-5_8 · Cited by 1
Wiggins, B. S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001132 · Cited by 2
Cardiovascular Effects of Metformin
Kurmanbekova, B. T., & Noruizbaeva, A. M. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-02-12 · Cited by 2
Multiple miRNA Regulation of Lipoprotein Lipase
Charrière, S., & Moulin, P. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_98 · Cited by 1
Андреевич, А. В. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-303 · Cited by 1
Safely lowering triglycerides through ANGPTL4 inhibition
Wulff, A. B. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00988-2 · Cited by 1
Genetics and Genomics of Coronary Artery Disease
Yamada, Y., & Yasukochi, Y. (2018) · Springer eBooks · doi:10.1007/978-3-319-66114-8_22 · Cited by 2
Prospective Advances in Non-coding RNAs Investigation
Jan, M. I., Ali, T., Ishtiaq, A., Mushtaq, I., & Murtaza, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1671-9_24 · Cited by 1
RNAi for livestock improvement
Shah, U. N., Gnanasekaran, S., Mondal, S., Reddy, I. J., Nandi, S., Gupta, P. S., & Das, D. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820595-2.00007-2 · Cited by 1
Smelser, D. T., Hannan, F. M., Metpally, R. P. R., Krishnamurthy, S. B., Carey, D. J., Thakker, R. V., & Breitwieser, G. E. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/644559 · Cited by 1
Self-citationThe Genetics of Coronary Heart Disease
Erdmann, J., & Venegas, M. L. M. (2019) · Cardiac and vascular biology · doi:10.1007/978-3-030-27371-2_4 · Cited by 1
Ye, X., Wang, X., & Jia, J. (2023) · medRxiv · doi:10.1101/2023.12.05.23299535 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
La PCSK9 sigue dando sorpresas
Pocoví, M. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.03.001
Genetische Variante des ANGPTL4-Gens schützt vor Myokardinfarkten
Özcelik, C. (2016) · Der Kardiologe · doi:10.1007/s12181-016-0066-4
“Zwei zeitgleich publizierte genetische Studien fanden nun eine signifikante Assoziation zwischen genetischen Varianten im Angiopoietin-like-4-(ANGPTL4-)Gen, das den Triglyzeridspiegel beeinflusst, und dem KHK-Risiko [2, 3].”
BackgroundInfluentialMetabolismo del colesterol y mecanismos de acción de los fármacos hipolipemiantes
Canals, J. (2017) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2017.02.003
Multiple miRNA Regulation of Lipoprotein Lipase
Charrière, S., & Moulin, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_98-1
The shape of things to come in lipid management: a feast of reason
Watts, G. F., & Stroes, E. S. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000467
Pulk, R., Graham, J., Lichtenberg, F. R., Maeng, D. D., Williams, M. S., & Wright, E. A. (2019) · NBER Chapters · doi:10.7916/d8-km1e-0z67
Progress in genetics of coronary artery disease
Gamal, R. (2017) · Egyptian Journal of Medical Human Genetics · doi:10.1016/j.ejmhg.2017.11.001
“By contrast, rare mutations in APOC3 and ANGPTL4, the protein products of which inhibit LPL, are associated with decreased CAD risk [19].”
VIII. Development of New Strategy and Modality of Lipid Management
Okazaki, H. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.735
Murawska, K., Szternel, Ł., & Sypniewska, G. (2018) · Medical Research Journal · doi:10.5603/mrj.a2018.0027
“[17] showed in their studies that in 1661 individuals with heterozygous missense mutations of ANGPTL4 protein, the triglycerides level was lower Figure 3.”
BackgroundResultRegulation of Lipoprotein Lipase Activity : an In-vitro Study of a Complex and Dynamic System
Kovrov, O. (2019) · DiVA at Umeå University (Umeå University)
Ozaki, K., & Tanaka, T. (2019) · Springer eBooks · doi:10.1007/978-981-13-8177-5_2
Nutrigenética e síndrome metabólica
Rios, D. L. S., Oliveira, M. C. A. M., & de Assis, V. D. C. D. (2018) · doi:10.7476/9786588211113.0008
Emerging New Lipid-Lowering Therapies in the Statin Era
Jang, A. Y., Jo, S., & Koh, K. K. (2021) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2021.1.e5
Genetics of (Premature) Coronary Artery Disease
Erdmann, J., & Schunkert, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-44203-7_22
Genetics of (Premature) Coronary Artery Disease
Erdmann, J., & Schunkert, H. (2020) · Springer eBooks · doi:10.1007/978-3-030-45457-9_24
Regulatory mechanisms of fasting
Ruppert, P. M. M. (2020) · doi:10.18174/527117
Kazlauskas, A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736655920.793567842
Arvanitis, M., Post, W. S., & Battle, A. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_3
Atypical Polycystic Kidney Disease in Individuals Heterozygous for ALG8 Protein-truncating variantsPreprint
Apple, B. J., Sartori, G., Moore, B. S., Chintam, K., Singh, G., Mohan, P., Strande, N. T., Mirshahi, T., Triffo, W. J., & Chang, A. R. (2022) · medRxiv · doi:10.1101/2022.07.13.22277451
Icosapent Ethyl for the Prevention of Cardiovascular Events
Lloyd, J. (2019) · EMJ Cardiology · doi:10.33590/emjcardiol/10311840
Park, J. K., Bafna, S., Forrest, I. S., Duffy, Á., Márquez‐Luna, C., Petrazzini, B. O., Vy, H. M. T., Jordan, D. M., Verbanck, M., Narula, J., et al. (2023) · eLife · doi:10.7554/elife.80560.sa2
Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering
Gagnon, É., & Arsenault, B. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000977
Outland, E. H., Xin, Y., Dickson, A. L., Mundo, S., Tao, R., Zhong, X. Y., Karakoc, G., Serley, S., Jiang, L., Cox, N. J., et al. (2025) · medRxiv · doi:10.1101/2025.03.07.25323588 · Cited by 1
Time-Restricted Eating, ANGPTL4, and Reduction in Residual Cardiovascular Risk
Gugliucci, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197026 · Cited by 1
“[55,108,125,126,151,166,169,170] dietary interventions such as TRE are increasingly recognized for their potential benefits in metabolic health and weight management.”
The tear film protein profile in blepharitis
Muttuvelu, D. V. (2025) · Acta Ophthalmologica · doi:10.1111/aos.16762
Additional file 4 of Exome-based investigation of the genetic basis of human pigmentary glaucoma
van der Heide, C. J., Goar, W., Meyer, K. J., Alward, W. L. M., Boese, E. A., Sears, N. C., Roos, B. R., Kwon, Y. H., DeLuca, A. P., Siggs, O. M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14853017
Li, W., Wang, Y., 黄日太, Feng, L., Xu, G., Wang, W., & Xue, S. (2024) · Figshare · doi:10.6084/m9.figshare.25200728
Additional file 1 of Exome-based investigation of the genetic basis of human pigmentary glaucoma
van der Heide, C. J., Goar, W., Meyer, K. J., Alward, W. L. M., Boese, E. A., Sears, N. C., Roos, B. R., Kwon, Y. H., DeLuca, A. P., Siggs, O. M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14853008
Li, W., Wang, Y., 黄日太, Feng, L., Xu, G., Wang, W., & Xue, S. (2024) · Figshare · doi:10.6084/m9.figshare.25200645
Sun, T., Zhan, W., Wei, L., Xu, Z., Fan, L., Zhuo, Y., Wang, C., & Zhang, J. (2021) · Figshare · doi:10.6084/m9.figshare.16944500
Additional file 2 of Exome-based investigation of the genetic basis of human pigmentary glaucoma
van der Heide, C. J., Goar, W., Meyer, K. J., Alward, W. L. M., Boese, E. A., Sears, N. C., Roos, B. R., Kwon, Y. H., DeLuca, A. P., Siggs, O. M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14853011
Yang, F., Xu, F., Zhang, H., Gill, D., Larsson, S. C., Li, X., Cui, H., & Yuan, S. (2023) · Figshare · doi:10.6084/m9.figshare.24741992
Yang, F., Xu, F., Zhang, H., Gill, D., Larsson, S. C., Li, X., Cui, H., & Yuan, S. (2024) · Figshare · doi:10.6084/m9.figshare.24742994
Additional file 3 of Exome-based investigation of the genetic basis of human pigmentary glaucoma
van der Heide, C. J., Goar, W., Meyer, K. J., Alward, W. L. M., Boese, E. A., Sears, N. C., Roos, B. R., Kwon, Y. H., DeLuca, A. P., Siggs, O. M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14853014
Li, W., Wang, Y., 黄日太, Feng, L., Xu, G., Wang, W., & Xue, S. (2024) · Figshare · doi:10.6084/m9.figshare.26679272
Soper, E. R., Casasanta, N. A., Dubois, B., Belbin, G. M., Kenny, E. E., & Abul‐Husn, N. S. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.03.004 · Cited by 1
Genome sequencing and Big Data analysis
Carey, D. J., & Smelser, D. T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00032-3
Self-citationRutault, A. (2025) · theses.fr (ABES) · doi:10.70675/3043b5b4z2339z4ad9z8616zd229a6ccbb8f
Khaled, R., El-Zayat, E., Ragheb, M. A., Abdelrahman, S. E., & Matboli, M. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04926-w
“Dewey et al. proved that variants in ANGPTL4 were significantly associated with reduced plasma TGs, which also affects lipid metabolism and consequently reduces the risk of coronary heart disease [59].”
Associations of ANGPTL3/4/8 proteins and complexes with heart failure and heart failure mortality
Silbernagel, G., Maas, A.-C., Li, H., Lemen, D., Chen, Y. Q., Zhen, E. Y., Wen, Y., Kleber, M. E., Delgado, G., Moissl-Blanke, A., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02973-8
Sun, Y., Li, M. W., Zhang, D., Cheng, Y., Liu, Y., Niu, J., Ge, H., Liu, X., & Han, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1784318
“In addition, several population-based observational studies have demonstrated that ANGPTL4 loss-of-function variants are associated with lower TG levels, higher HDL-C levels, and reduced coronary artery disease (CAD) risk, supporting its potential utility as a biomarker for CAD (13 – 15).”
Naydenov, Y., Karamfilova, V., Nikolova, D., Yordanova, S., Kamenov, Z. A., Hristova, J., & Gateva, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103631
“Loss-of-function variants in ANGPTL4 are consistently associated with lower plasma triglycerides, higher HDL-cholesterol, and reduced cardiovascular risk, supporting a protective metabolic role [11,30].”
Research progress on targeted regulatory proteins in the prevention and treatment of atherosclerosis
Wei, Y., Zhang, F., Liao, Y., Zhao, Y., & Guo, J. Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1791961
“They govern the clearance of circulating triglycerides and triglyceride-rich lipoprotein remnants, playing a pivotal role in the pathogenesis of atherosclerotic cardiovascular disease (206, 207).”
Björnson, E., & Adiels, M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01442-y
“Human genetic studies of pathways such as LPL, APOC3, ANGPTL3, and ANGPTL4 strongly suggest that TRL metabolism is causal [13–16].”
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Ariyanto, E. F., Lastialno, M. P., Fitri, D. N., Arvieri, S. A., Farahana, A. K., Sudirman, G. S. J., Widhiyanto, M. P. A., Rahmatika, N. S., Sabarina, P. P., Pratiwi, Y. S., et al. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s604906
“112,113 In nutrient-depleted conditions, PPARs upregulate ANGPTL4 expression to promote the mobilization of free fatty acids from the adipose tissue into the circulation while preventing lipid uptake.”
Wu, Y., Liu, S., Luo, W., Rao, J., He, W., Windsor, J., Sutton, R., Mukherjee, R., Shi, N., & Huang, W. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-120485
Contrastive alignment transfers proteomic predictive signals to metabolomics dataPreprint
Hu, D., Chiara, R., Avelli, M. P., Jordi, M., Jensen, L. J., & Rasmussen, S. (2026) · medRxiv · doi:10.64898/2026.08.14.26360447
Shetty, S. K., Sylvers-Davie, K. L., & Davies, B. S. J. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101124
“Systemic loss of ANGPTL4 function reduces plasma triglyceride levels in both mice and humans (4 – 7).”
Mahjoubin‐Tehran, M., Eid, A. H., Jamialahmadi, T., Sheeha, B. H. B., Althomali, O. W., Ahmad, S., Almahmeed, W. A., & Sahebkar, A. (2026) · Bariatric Surgical Practice and Patient Care · doi:10.1177/2168023x261479394
“59 In the current investigation, we found that the RYGB downregulates ANGPTL4, which could be an underlying mechanism for the cardiovascular risk reduction associated with this surgery.”
Thoracic aortic disease: prognostic role of gene variants and polygenic risk scores
DePaolo, J. S., Smelser, D. T., Guo, D., Abramowitz, S. A., Sisti, G., Judy, R., Desai, N. D., Szeto, W. Y., Levin, M. G., Mirshahi, H. S., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag518
Self-citationYang, G., Zhang, D. Y., Fischman, C. J., Cuchel, M., Suszták, K., & Rader, D. J. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.06.015
Biological age uncertainty reveals discordant aging and predicts human healthspanPreprint
Li, Y., Feng, G., Yan, S., Huang, Q., Jin, J., Wang, Y., Pei, Z., Tay, L. X., Li, K., Pan, Z., et al. (2026) · medRxiv · doi:10.64898/2026.09.26.26364091
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
Blood proteome-wide Mendelian randomization reveals molecular pleiotropy in coronary artery disease
Moncla, L.-H. M., Mathieu, S., Briend, M., Duclos, V., Rufiange, A., Arsenault, B. J., & Mathieu, P. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121923
Zhang, Z., Peng, G., Zhou, Y., Lu, Y., 陶福林, & Xu, C. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.10.013
Metadata
- Authors
- Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., Leader, J. B., Murray, M. F., Ritchie, M. D., Kirchner, H. L., Ledbetter, D. H., Penn, J., Lopez, A., Borecki, I. B., Overton, J. D., Reid, J. G., Carey, D. J., Murphy, A. J., Yancopoulos, G. D., Baras, A., Gromada, J., & Shuldiner, A. R.
- Affiliations
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-24
- Volume
- 374
- Issue
- 12
- Pages
- 1123-1133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4900689
- OpenAlex
- W2323589075
- Cited by
- 497
- References
- 40
- Citations by year
- 2026: 33 · 2025: 40 · 2024: 38 · 2023: 36 · 2022: 41 · 2021: 63 · 2020: 52 · 2019: 51 · 2018: 53 · 2017: 57 · 2016: 33
- FWCI
- 53.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- ANGPTL4, loss-of-function mutations, coronary artery disease, triglycerides, HDL cholesterol, lipoprotein lipase, genetic variants, monoclonal antibody inhibition, serum lipids, genetic association studies
- MeSH terms
- Angiopoietin-Like Protein 4, Aged, Animals, Cholesterol, Coronary Artery Disease, Disease Models, Animal, Female, Heterozygote, Humans, Macaca mulatta, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Gene Silencing, Angiopoietins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.